These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 32217661)

  • 21. Identification of a novel WNK1-ROS1 fusion in a lung adenocarcinoma sensitive to crizotinib.
    Liu Y; Liu T; Li N; Wang T; Pu Y; Lin R
    Lung Cancer; 2019 Mar; 129():92-94. PubMed ID: 30797499
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib.
    Patil T; Smith DE; Bunn PA; Aisner DL; Le AT; Hancock M; Purcell WT; Bowles DW; Camidge DR; Doebele RC
    J Thorac Oncol; 2018 Nov; 13(11):1717-1726. PubMed ID: 29981925
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ROS1 rearrangements define a unique molecular class of lung cancers.
    Bergethon K; Shaw AT; Ou SH; Katayama R; Lovly CM; McDonald NT; Massion PP; Siwak-Tapp C; Gonzalez A; Fang R; Mark EJ; Batten JM; Chen H; Wilner KD; Kwak EL; Clark JW; Carbone DP; Ji H; Engelman JA; Mino-Kenudson M; Pao W; Iafrate AJ
    J Clin Oncol; 2012 Mar; 30(8):863-70. PubMed ID: 22215748
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.
    Mazières J; Zalcman G; Crinò L; Biondani P; Barlesi F; Filleron T; Dingemans AM; Léna H; Monnet I; Rothschild SI; Cappuzzo F; Besse B; Thiberville L; Rouvière D; Dziadziuszko R; Smit EF; Wolf J; Spirig C; Pecuchet N; Leenders F; Heuckmann JM; Diebold J; Milia JD; Thomas RK; Gautschi O
    J Clin Oncol; 2015 Mar; 33(9):992-9. PubMed ID: 25667280
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ROS1-Rearranged Lung Cancer Successfully Resected after Response to Crizotinib: A Case Report.
    Shimizu N; Tanaka Y; Tachihara M; Maniwa Y
    Kobe J Med Sci; 2022 Feb; 67(4):E143-E145. PubMed ID: 35368001
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Progressive Dry Cough in a Patient With ROS1-Rearranged Lung Adenocarcinoma Undergoing Crizotinib Therapy.
    Chu CY; Er HP; Lin CC
    JAMA Oncol; 2021 Jan; 7(1):124-125. PubMed ID: 33001162
    [No Abstract]   [Full Text] [Related]  

  • 27. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.
    Kim HR; Lim SM; Kim HJ; Hwang SK; Park JK; Shin E; Bae MK; Ou SH; Wang J; Jewell SS; Kang DR; Soo RA; Haack H; Kim JH; Shim HS; Cho BC
    Ann Oncol; 2013 Sep; 24(9):2364-70. PubMed ID: 23788756
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Crizotinib Treatment Combined with Resection and Whole-brain Radiation Therapy 
in A ROS1 Rearranged Lung Adenocarcinoma with Brain Metastasis: 
Case Report and Literature Review].
    Zhang M; Nie L; Zhang J
    Zhongguo Fei Ai Za Zhi; 2016 Aug; 19(8):525-9. PubMed ID: 27561802
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Crizotinib in
    Landi L; Chiari R; Tiseo M; D'Incà F; Dazzi C; Chella A; Delmonte A; Bonanno L; Giannarelli D; Cortinovis DL; de Marinis F; Borra G; Morabito A; Gridelli C; Galetta D; Barbieri F; Grossi F; Capelletto E; Minuti G; Mazzoni F; Verusio C; Bria E; Alì G; Bruno R; Proietti A; Fontanini G; Crinò L; Cappuzzo F
    Clin Cancer Res; 2019 Dec; 25(24):7312-7319. PubMed ID: 31416808
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prolonged Response to Afatinib and Crizotinib in a Rare Case of
    Plomer E; Früh M; Lauber A; Demmer I; Jochum W; Koster KL
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891886
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of a novel NPM1-ROS1 fusion in a lung adenocarcinoma and sensitive to crizotinib treatment.
    Ma H; Zhang Q; Duan Q; Zhang Q; Li F
    Lung Cancer; 2021 Feb; 152():196-198. PubMed ID: 33386152
    [No Abstract]   [Full Text] [Related]  

  • 32. ROS1-rearranged NSCLC With Secondary Resistance Mutation: Case Report and Current Perspectives.
    Guisier F; Piton N; Salaun M; Thiberville L
    Clin Lung Cancer; 2019 Nov; 20(6):e593-e596. PubMed ID: 31395437
    [No Abstract]   [Full Text] [Related]  

  • 33. Successful Treatment of ROS1-rearranged Lung Cancer Complicated by Hypertrophic Pulmonary Osteoarthropathy with Crizotinib Therapy.
    Katsurada N; Tachihara M; Jimbo N; Koyama K; Nakata K; Nagano T; Yamamoto M; Kamiryo H; Kobayashi K; Nishimura Y
    Intern Med; 2019 May; 58(10):1467-1471. PubMed ID: 30626830
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Elevation of tumor mutation burden in ROS1-fusion lung adenocarcinoma resistant to crizotinib: A case report.
    Yang T; Xu R; Yan B; Li F; Liu H
    Medicine (Baltimore); 2018 Dec; 97(52):e13797. PubMed ID: 30593165
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Histopathologic characteristics of advanced-stage ROS1-rearranged non-small cell lung cancers.
    Park E; Choi YL; Ahn MJ; Han J
    Pathol Res Pract; 2019 Jul; 215(7):152441. PubMed ID: 31085007
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Choroidal metastasis response to crizotinib in a ROS1-rearranged NSCLC patient.
    Lu S; Azada MC; Ou SH
    Lung Cancer; 2015 Feb; 87(2):207-9. PubMed ID: 25558789
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term progression-free survival in an advanced lung adenocarcinoma patient harboring EZR-ROS1 rearrangement: a case report.
    Dong L; Xia J; Zhang J; Zhang Y; Zhu N; Zhang P; Zhang Y; Zhang X; Li S
    BMC Pulm Med; 2018 Jan; 18(1):13. PubMed ID: 29361925
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib.
    Bos M; Gardizi M; Schildhaus HU; Heukamp LC; Geist T; Kaminsky B; Zander T; Nogova L; Scheffler M; Dietlein M; Kobe C; Holstein A; Maintz D; Büttner R; Wolf J
    Lung Cancer; 2013 Jul; 81(1):142-3. PubMed ID: 23558310
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
    Facchinetti F; Loriot Y; Kuo MS; Mahjoubi L; Lacroix L; Planchard D; Besse B; Farace F; Auger N; Remon J; Scoazec JY; André F; Soria JC; Friboulet L
    Clin Cancer Res; 2016 Dec; 22(24):5983-5991. PubMed ID: 27401242
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical significance of ROS1 5' deletions in non-small cell lung cancer.
    Capizzi E; Dall'Olio FG; Gruppioni E; Sperandi F; Altimari A; Giunchi F; Fiorentino M; Ardizzoni A
    Lung Cancer; 2019 Sep; 135():88-91. PubMed ID: 31447007
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.